Introduction
Many of you, if you follow Bristol-Myers Squibb, all know that they recently merged with Celgene and they’ve now become a much bigger company. What’s been happening in big pharma, even the big names like Merck and Pfizer, these were very strong growth stocks years ago, but in more recent times their growth has slowed quite a bit.
Growth is expected to be real strong going out for the next couple of years. So all in all, I really like Bristol-Myers. I think it’s a great selection for anyone who’s looking for above-average dividend income, but also some capital gain potential, especially out over the next three to five years.
Company Description
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
FAST Graphs Analyze Out Loud Video on Bristol-Myers Squibb:
Disclosure: Long BMY.
Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.
Try FAST Graphs for FREE Today!